[go: up one dir, main page]

WO2024044633A3 - Oxytocin derivatives and methods of use - Google Patents

Oxytocin derivatives and methods of use Download PDF

Info

Publication number
WO2024044633A3
WO2024044633A3 PCT/US2023/072729 US2023072729W WO2024044633A3 WO 2024044633 A3 WO2024044633 A3 WO 2024044633A3 US 2023072729 W US2023072729 W US 2023072729W WO 2024044633 A3 WO2024044633 A3 WO 2024044633A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
oxytocin
compounds
oxytocin derivatives
disclosure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2023/072729
Other languages
French (fr)
Other versions
WO2024044633A2 (en
Inventor
Alex Kiselyov
Christian L. ROTH
Clinton T. ELFERS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Seattle Childrens Hospital
Original Assignee
Seattle Childrens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seattle Childrens Hospital filed Critical Seattle Childrens Hospital
Publication of WO2024044633A2 publication Critical patent/WO2024044633A2/en
Publication of WO2024044633A3 publication Critical patent/WO2024044633A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/16—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/16—Cyclodextrin; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Provided herein are compounds of formula (I). In certain embodiments, the compounds of the disclosure are analogs of oxytocin. In certain embodiments, the compounds of the disclosure have significantly larger half-lives than oxytocin, and are useful in the treatment of obesity and in the reduction of appetite or food intake in a subject.
PCT/US2023/072729 2022-08-23 2023-08-23 Oxytocin derivatives and methods of use Ceased WO2024044633A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263373280P 2022-08-23 2022-08-23
US63/373,280 2022-08-23

Publications (2)

Publication Number Publication Date
WO2024044633A2 WO2024044633A2 (en) 2024-02-29
WO2024044633A3 true WO2024044633A3 (en) 2024-04-04

Family

ID=90014186

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/072729 Ceased WO2024044633A2 (en) 2022-08-23 2023-08-23 Oxytocin derivatives and methods of use

Country Status (1)

Country Link
WO (1) WO2024044633A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040235956A1 (en) * 2000-01-11 2004-11-25 Atossa Healthcare, Inc. Long-acting oxytocin analogues for the treatment and prevention of breast cancer and psychiatric disorders
US20110044905A1 (en) * 2008-03-31 2011-02-24 Ferring B.V. Oxytocin analogues
US20170081368A1 (en) * 2014-06-06 2017-03-23 Hoffmann-La Roche Inc. Peptides as oxytocin agonists

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040235956A1 (en) * 2000-01-11 2004-11-25 Atossa Healthcare, Inc. Long-acting oxytocin analogues for the treatment and prevention of breast cancer and psychiatric disorders
US20110044905A1 (en) * 2008-03-31 2011-02-24 Ferring B.V. Oxytocin analogues
US20170081368A1 (en) * 2014-06-06 2017-03-23 Hoffmann-La Roche Inc. Peptides as oxytocin agonists

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CLINTON T. ELFERS: "Novel Long-Acting Oxytocin Analog with Increased Efficacy in Reducing Food Intake and Body Weight", INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, MOLECULAR DIVERSITY PRESERVATION INTERNATIONAL (MDPI), BASEL, CH, vol. 23, no. 19, Basel, CH , pages 11249, XP093158889, ISSN: 1422-0067, DOI: 10.3390/ijms231911249 *
CLINTON T. ELFERS: "Robust Reductions of Body Weight and Food Intake by an Oxytocin Analog in Rats", FRONTIERS IN PHYSIOLOGY, FRONTIERS RESEARCH FOUNDATION, CH, vol. 12, 27 September 2021 (2021-09-27), CH , XP093158887, ISSN: 1664-042X, DOI: 10.3389/fphys.2021.726411 *

Also Published As

Publication number Publication date
WO2024044633A2 (en) 2024-02-29

Similar Documents

Publication Publication Date Title
ZA202401567B (en) Ring-modified proline short peptide compound and use thereof
MX2009006742A (en) Novel compounds.
EP2639229A3 (en) Thiazole Derivative and use thereof as VAP-1 Inhibitor
NZ787393A (en) New methylquinazolinone derivatives
UA83233C2 (en) Substituted 2-aminotetralin for the treatment of depression
UA84271C2 (en) Formate salt of o-desmethyl-venlafaxine
EP4553071A3 (en) Methods for improving mitophagy in subjects
MY137039A (en) Thiophene glycoside derivatives, processes for the preparation, medicaments comprising these compounds, and the use thereof
NO20055649L (en) Substituted dihydroquinazoline with antivial properties
NO20082144L (en) Mixture of iron and copper salts that mask metallic taste
WO2004089279A3 (en) Long-acting derivatives of pyy agonists
MX2009013730A (en) Amine compound and pharmaceutical use thereof.
WO2005044192A3 (en) Triazole compounds and uses related thereto
EP1408038A3 (en) Imidazole deriviatives and their use as peripherally-selective inhibitors of dopamine-beta-hydroxylase
GB0321003D0 (en) Compounds, compositions and uses
GEP20094826B (en) 3- or 4-monosubstituted phenol and thiophenol derivatives useful as h3 ligands
DE60232173D1 (en) USE OF SULFONAMIDE DERIVATIVES IN THE TREATMENT OF ADIPOSITAS OR TO REDUCE FOOD RECEPTION
MY139107A (en) Substituted n-cyclohexylimidazolinones, process for their preparation and their use as medicaments.
MY145823A (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity
WO2024044633A3 (en) Oxytocin derivatives and methods of use
MXPA06004308A (en) Isopentyl carboxanilides for combating undesired micro-organisms.
MX2022013692A (en) 3-azabicyclo(3.1.0)hexane derivatives having kdm5 inhibitory activity and use thereof.
CN114929707A (en) EED inhibitor and preparation method and application thereof
CA2501321A1 (en) Pharmaceutical composition comprising crystalline sibutramine methanesulfonate hemihydrate
MX2025010357A (en) Irak4 degrader and use thereof

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 23858264

Country of ref document: EP

Kind code of ref document: A2